Pascal Mayer | |
---|---|
Born | July 14, 1963 |
Nationality | French |
Known for | His research paved the way for cheap and rapid DNA sequencing |
Pascal Mayer is a French biophysicist and entrepreneur specializing in biomolecular analyses for diagnostics, predictive medicine and drug discovery.
He is known for his work that led to the development of a next-generation for an inexpensive and rapid DNA sequencing technology. [1] [2] [3] that would become the basis of Illumina technology, and for which he was awarded the 2022 Breakthrough Prize in life sciences category. He is currently the president of Alphanosos.
He was awarded the Canada Gairdner International Award [4] in 2024.
He is the co-founder of Alphanosos, a company in applied AI for sustainable health and bio-industries that develops natural health products based on patentable mixes of plant extracts.
Pascal Mayer was born in 1963 in Moselle, where he grew up. He graduated in 1988 with a Master's degree (DEA) in Molecular Biology from the Louis Pasteur University [5] of Strasbourg, where he obtained his PhD in Macromolecular Biophysics in 1991
His thesis was devoted to the development of an automated apparatus for measuring electrical birefringence on gel and to the experimental study of DNA dynamics during pulsed-field electrophoresis.
From 1991 to 1994, he completed a postdoctoral fellowship at the University of Ottawa (Canada) where he demonstrated how a new method for separating DNA in free solution could significantly improve DNA sequencing methods.
During a second postdoctoral fellowship at the Paul Pascal Research Center of the CNRS, from 1994 to 1996, he invented a method and wrote software to analyze video-microscopy images of blurred moving objects (DNA molecules) using spatio-temporal correlation maps.
In November 1996, he joined the GlaxoSmithKline group in Geneva, where his work led to the filing of patents revealing the new method of massive parallel DNA sequencing, subsequently acquired by the British company Solexa created by Shankar Balasubramanian and David Klenerman, whose start-up was ultimately acquired by Illumina. [6] These patents have enabled the creation of a rapid, robust and inexpensive DNA sequencing technique (one day and around $600 for the resequencing of a complete human genome), which is now used on a large scale. In this respect, Pascal Mayer received the Breakthrough Prize in life sciences category in 2022 (alongside these two British scientists) [7] and the Canada Gairdner International Award in 2024. [8] This technology enabled the rapid sequencing of SARS-CoV-2 (Covid-19) [9] in 2020 and the regular monitoring of genetic mutations of the different variants.
In 2014, he co-founded the company Alphanosos, located in Riom (Auvergne). In his company he has made several developments so far :
Genomics is an interdisciplinary field of molecular biology focusing on the structure, function, evolution, mapping, and editing of genomes. A genome is an organism's complete set of DNA, including all of its genes as well as its hierarchical, three-dimensional structural configuration. In contrast to genetics, which refers to the study of individual genes and their roles in inheritance, genomics aims at the collective characterization and quantification of all of an organism's genes, their interrelations and influence on the organism. Genes may direct the production of proteins with the assistance of enzymes and messenger molecules. In turn, proteins make up body structures such as organs and tissues as well as control chemical reactions and carry signals between cells. Genomics also involves the sequencing and analysis of genomes through uses of high throughput DNA sequencing and bioinformatics to assemble and analyze the function and structure of entire genomes. Advances in genomics have triggered a revolution in discovery-based research and systems biology to facilitate understanding of even the most complex biological systems such as the brain.
A DNA sequencer is a scientific instrument used to automate the DNA sequencing process. Given a sample of DNA, a DNA sequencer is used to determine the order of the four bases: G (guanine), C (cytosine), A (adenine) and T (thymine). This is then reported as a text string, called a read. Some DNA sequencers can be also considered optical instruments as they analyze light signals originating from fluorochromes attached to nucleotides.
BGI Group, formerly Beijing Genomics Institute, is a Chinese genomics company with headquarters in Yantian, Shenzhen. The company was originally formed in 1999 as a genetics research center to participate in the Human Genome Project. It also sequences the genomes of other animals, plants and microorganisms.
In bioinformatics, sequence assembly refers to aligning and merging fragments from a longer DNA sequence in order to reconstruct the original sequence. This is needed as DNA sequencing technology might not be able to 'read' whole genomes in one go, but rather reads small pieces of between 20 and 30,000 bases, depending on the technology used. Typically, the short fragments (reads) result from shotgun sequencing genomic DNA, or gene transcript (ESTs).
Louis Pasteur University, also known as Strasbourg I, was a large university in Strasbourg, Alsace, France. As of 15 January 2007, there were 18,847 students enrolled at the university, including around 3,000 foreign students. Research and teaching at ULP concentrated on the natural sciences, technology and medicine. On 1 January 2009, Louis Pasteur University became part of the refounded University of Strasbourg and lost its status as an independent university.
Luc Montagnier was a French virologist and joint recipient, with Françoise Barré-Sinoussi and Harald zur Hausen, of the 2008 Nobel Prize in Physiology or Medicine for his discovery of the human immunodeficiency virus (HIV). He worked as a researcher at the Pasteur Institute in Paris and as a full-time professor at Shanghai Jiao Tong University in China.
Pierre Chambon was the founder of the Institute for Genetics and Cellular and Molecular Biology in Strasbourg, France. He was one of the leading molecular biologists who utilized gene cloning and sequencing technology to first decipher the structure of eukaryotic genes and their modes of regulation. His major contributions to science include the identification of RNA polymerase II (B), the identification of transcriptional control elements, the cloning and dissection of nuclear hormone receptors, revealing their structure and showing how they contribute to human physiology. His group was also one of the first to demonstrate, biochemically and electron-microscopically, that the nucleosome is the smallest unit of chromatin. He accomplished much of his work in the 1970s – 1990s.
DNA sequencing is the process of determining the nucleic acid sequence – the order of nucleotides in DNA. It includes any method or technology that is used to determine the order of the four bases: adenine, guanine, cytosine, and thymine. The advent of rapid DNA sequencing methods has greatly accelerated biological and medical research and discovery.
Polony is a contraction of "polymerase colony," a small colony of DNA.
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
Mostafa Ronaghi is an Iranian molecular biologist, specializing in DNA sequencing methodology. He earned his Ph.D. from the Royal Institute of Technology in Sweden in 1998.
Whole genome sequencing (WGS) is the process of determining the entirety, or nearly the entirety, of the DNA sequence of an organism's genome at a single time. This entails sequencing all of an organism's chromosomal DNA as well as DNA contained in the mitochondria and, for plants, in the chloroplast.
Manteia Predictive Medicine S.A. was a start-up company created in November 2000 as a spin-off of Serono, a Swiss-based biotechnology company, now part of Merck-Serono, by private founders. Its aim was to provide preventive and curative treatment guidelines for common and complex diseases. These guidelines were envisaged as composed of two parts:
Massive parallel sequencing or massively parallel sequencing is any of several high-throughput approaches to DNA sequencing using the concept of massively parallel processing; it is also called next-generation sequencing (NGS) or second-generation sequencing. Some of these technologies emerged between 1993 and 1998 and have been commercially available since 2005. These technologies use miniaturized and parallelized platforms for sequencing of 1 million to 43 billion short reads per instrument run.
The $1,000 genome refers to an era of predictive and personalized medicine during which the cost of fully sequencing an individual's genome (WGS) is roughly one thousand USD. It is also the title of a book by British science writer and founding editor of Nature Genetics, Kevin Davies. By late 2015, the cost to generate a high-quality "draft" whole human genome sequence was just below $1,500.
Jennifer Anne Doudna is an American biochemist who has pioneered work in CRISPR gene editing, and made other fundamental contributions in biochemistry and genetics. Doudna was one of the first women to share a Nobel in the sciences. She received the 2020 Nobel Prize in Chemistry, with Emmanuelle Charpentier, "for the development of a method for genome editing." She is the Li Ka Shing Chancellor's Chair Professor in the department of chemistry and the department of molecular and cell biology at the University of California, Berkeley. She has been an investigator with the Howard Hughes Medical Institute since 1997.
Sir Shankar Balasubramanian is an Indian-born British chemist and Herchel Smith Professor of Medicinal Chemistry in the Department of Chemistry at the University of Cambridge, Senior Group Leader at the Cancer Research UK Cambridge Institute and Fellow of Trinity College, Cambridge. He is recognised for his contributions in the field of nucleic acids. He is scientific founder of Solexa and biomodal.
Sir David Klenerman is a British biophysical chemist and a professor of biophysical chemistry at the Department of Chemistry at the University of Cambridge and a Fellow of Christ's College, Cambridge.
Gerardo Turcatti is a Swiss-Uruguayan chemist who specialises in chemical biology and drug discovery. He is a professor at the École Polytechnique Fédérale de Lausanne (EPFL) and director of the Biomolecular Screening Facility at the School of Life Sciences there.
MGI or MGI Tech is a Chinese biotechnology company, which provides a line of products and technologies that serves the genetic sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in Shenzhen, China.